相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Abdominal Symptoms Assessed With the CFAbd-Score are Associated With Intestinal Inflammation in Patients With Cystic Fibrosis
Anke Jaudszus et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2022)
Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score
Jochen G. Mainz et al.
FRONTIERS IN PHARMACOLOGY (2022)
PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy
Dave P. Nichols et al.
JOURNAL OF CYSTIC FIBROSIS (2021)
Utilization of electronic patient-reported outcome measures in cystic fibrosis research: Application to the GALAXY study
Meghana Sathe et al.
JOURNAL OF CYSTIC FIBROSIS (2021)
Gastrointestinal Factors Associated With Hospitalization in Infants With Cystic Fibrosis: Results From the Baby Observational and Nutrition Study
Meghana Sathe et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2021)
An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB)
Margaret Rosenfeld et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
Energy Balance and Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations
Virginia A. Stallings et al.
JOURNAL OF PEDIATRICS (2018)
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study
Margaret Rosenfeld et al.
LANCET RESPIRATORY MEDICINE (2018)
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
Dominic Keating et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation
Chee Y. Ooi et al.
SCIENTIFIC REPORTS (2018)
Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings
Harold Tabori et al.
PLOS ONE (2017)
The PAC-SYM questionnaire for chronic constipation: defining the minimal important difference
Y. Yiannakou et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Confirmatory factor analysis of the Patient Assessment of Constipation-Symptoms (PAC-SYM) among patients with chronic constipation
Luca Neri et al.
QUALITY OF LIFE RESEARCH (2015)
Gastrointestinal Complications of Cystic Fibrosis
Daniel Gelfond et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Intestinal complications of cystic fibrosis
Drucy Borowitz et al.
CURRENT OPINION IN PULMONARY MEDICINE (2013)
Intestinal pH and Gastrointestinal Transit Profiles in Cystic Fibrosis Patients Measured by Wireless Motility Capsule
Daniel Gelfond et al.
DIGESTIVE DISEASES AND SCIENCES (2013)
A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect
Michael P. Boyle et al.
LANCET RESPIRATORY MEDICINE (2013)
Mechanisms of disease: Cystic fibrosis
SM Rowe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders
AM Rentz et al.
QUALITY OF LIFE RESEARCH (2004)
Cross-cultural development and validation of a patient self-administered questionnaire to assess quality of life in upper gastrointestinal disorders:: The PAGI-QOL©
C de la Loge et al.
QUALITY OF LIFE RESEARCH (2004)
Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration
E Bruzzese et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
分享论文
